Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Tablets × Head & Neck × Clear all

Phase

Phase NA 1 Phase 3 1 Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 11 Other hematologic neoplasm 5 Lymphoid 4 Gastrointestinal 4 Plasma cell 3 Dermatologic 3 Myeloid 2 Thoracic 1 Other 1 Head & Neck 1 Gynecologic 1 Genitourinary 1 Classical hematology 1 CNS 1

Conditions

Head and Neck Neoplasms 1 Deglutition Disorders 1

Interventions

Cisplatin 258 Radiotherapy 115 pembrolizumab 114 Cetuximab 111 Carboplatin 103 Docetaxel 102 Fluorouracil 79 Radiotherapy, Intensity-Modulated 78 Paclitaxel 77 Nivolumab 47 Gemcitabine 43 toripalimab 40 Radiation 39 Drug Therapy 33 Capecitabine 32 Magnetic Resonance Spectroscopy 27 camrelizumab 26 apatinib 26 Surgical Procedures, Operative 26 130-nm albumin-bound paclitaxel 24 tislelizumab 22 Bevacizumab 22 durvalumab 21 Chemoradiotherapy 21 Specimen Handling 19 sintilimab 18 Platinum 18 lenvatinib 17 Sorafenib 17 Albumin-Bound Paclitaxel 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07217938 2026-03-03

TRADstat

Peter MacCallum Cancer Centre, Australia

Phase 2 Recruiting

Deglutition Disorders, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡